Profile data is unavailable for this security.
About the company
Abionyx Pharma SA, formerly known as Cerenis Therapeutics Holding SA, is a France-based multinational biopharmaceutical company primarily engaged in the research, development and commercialization of High-density Lipoprotein (HDL) therapies for the treatment of cardiovascular and metabolic diseases. The Company’s product portfolio comprises Cerenis HDL and HDL enhancers that is designed to regress atherosclerotic plaque among patients at high risk of cardiovascular events, among others. Additionally, the Company has a portfolio of clinical and preclinical HDL programs. The Company is present in Labege in Midi-Pyrenees in France and in Ann Arbor in Michigan in the United States. In addition, it also operates through LYPRO Biosciences Inc.
- Revenue in EUR (TTM)4.33m
- Net income in EUR-4.60m
- Incorporated2005
- Employees51.00
- LocationAbionyx Pharma SABat. D 33-43 Avenue Georges PompidouBALMA 31130FranceFRA
- Phone+33 562249706
- Fax+33 562190417
- Websitehttps://www.abionyx.com/en/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novacyt SA | 21.91m | -31.84m | 29.27m | 234.00 | -- | 0.6243 | -- | 1.34 | -0.4511 | -0.494 | 0.3106 | 0.664 | 0.2354 | 2.34 | 5.27 | 93,627.49 | -34.20 | 5.59 | -39.09 | 7.29 | 63.35 | 66.74 | -145.32 | 9.83 | 4.59 | -7.23 | 0.2114 | -- | 84.82 | 11.35 | -60.50 | -- | 55.60 | -- |
| genOway SA | 20.95m | 1.29m | 29.85m | 148.00 | 15.80 | 1.11 | 7.38 | 1.42 | 0.1487 | 0.1487 | 2.42 | 2.12 | 0.594 | 0.8797 | 3.69 | 146,514.10 | 3.65 | 2.10 | 4.72 | 2.91 | 94.91 | 94.80 | 6.14 | 3.76 | 2.21 | -- | 0.4407 | -- | 10.04 | 18.46 | 16.79 | -- | 15.88 | -- |
| Fermentalg SA | 12.78m | -11.54m | 39.31m | 63.00 | -- | 1.39 | -- | 3.07 | -0.1242 | -0.1242 | 0.1353 | 0.3156 | 0.2472 | 7.91 | 3.29 | 199,734.40 | -17.09 | -18.10 | -21.17 | -20.59 | 20.94 | 25.51 | -69.14 | -147.66 | 1.83 | -- | 0.2368 | -- | 183.32 | 43.52 | 8.99 | -- | -4.91 | -- |
| Theranexus SA | 0.00 | -2.94m | 45.80m | 10.00 | -- | -- | -- | -- | -0.3641 | -0.3641 | 0.00 | -0.1923 | 0.00 | -- | -- | 0.00 | -66.82 | -44.47 | -148.89 | -50.85 | -- | -- | -- | -- | -- | -37.71 | 2.90 | -- | -- | -- | 74.15 | -- | -56.53 | -- |
| Eurofins Cerep SA | 40.46m | 7.15m | 80.20m | 207.00 | 11.21 | 1.12 | 8.38 | 1.98 | 1,418.43 | 1,418.43 | 8,027.24 | 14,234.14 | 0.4955 | 1.61 | 4.75 | 195,445.80 | 8.76 | 13.12 | 10.23 | 15.90 | 85.67 | 80.02 | 17.68 | 20.22 | 6.53 | -- | 0.0046 | -- | -8.20 | 5.46 | -6.34 | 10.36 | -- | -- |
| Ose Immunotherapeutics SA | 2.22m | -34.84m | 95.47m | 68.00 | -- | 1.88 | -- | 43.02 | -1.59 | -1.59 | 0.1009 | 2.26 | 0.0181 | -- | 0.4821 | 34,671.88 | -28.42 | -7.66 | -33.45 | -9.27 | -- | -- | -1,569.85 | -26.10 | -- | -- | 0.4331 | -- | 3,646.52 | 26.31 | 262.78 | -- | -25.52 | -- |
| Abionyx Pharma SA | 4.33m | -4.60m | 119.67m | 51.00 | -- | 21.30 | -- | 27.66 | -0.1317 | -0.1317 | 0.1238 | 0.1582 | 0.3033 | 17.39 | 7.16 | 84,823.53 | -32.25 | -26.53 | -43.11 | -38.31 | 17.78 | 15.59 | -106.31 | -131.06 | 1.35 | -- | 0.4281 | -- | -1.92 | -- | -24.53 | -- | -- | -- |
| Adocia SA | 10.35m | -9.71m | 130.20m | 77.00 | -- | -- | -- | 12.58 | -0.5622 | -0.5622 | 0.6343 | -0.0338 | 0.4068 | -- | 2.55 | 134,428.60 | -38.16 | -47.62 | -184.08 | -104.50 | -- | -- | -93.83 | -331.17 | 1.12 | -14.58 | 1.06 | -- | 333.49 | 34.18 | 55.95 | -- | -35.29 | -- |
| Maat Pharma SA | 3.92m | -31.13m | 134.03m | 60.00 | -- | 13.85 | -- | 34.17 | -2.15 | -2.15 | 0.270 | 0.5141 | 0.0786 | 11.22 | 0.5785 | 65,366.67 | -62.39 | -41.51 | -90.20 | -51.87 | 61.68 | -- | -793.83 | -976.99 | 2.21 | -29.53 | 0.6346 | -- | 44.34 | -- | -46.59 | -- | 42.53 | -- |
| Innate Pharma SA | 6.00m | -46.05m | 134.62m | 181.00 | -- | 25.73 | -- | 22.44 | -0.5497 | -0.5497 | 0.0714 | 0.0558 | 0.0491 | -- | 15.81 | 33,149.17 | -37.68 | -13.19 | -52.10 | -17.17 | 49.52 | 91.15 | -767.52 | -88.46 | -- | -- | 0.8401 | -- | -75.68 | -28.80 | -553.51 | -- | -64.08 | -- |
| Sensorion SA | 0.00 | -28.09m | 204.95m | 68.00 | -- | 2.10 | -- | -- | -0.0931 | -0.0931 | 0.00 | 0.1895 | 0.00 | -- | -- | 0.00 | -32.12 | -34.53 | -38.36 | -43.50 | -- | -- | -- | -- | -- | -- | 0.0265 | -- | -- | -- | -17.72 | -- | 98.90 | -- |
| Eurobio Scientific SA | 162.09m | 2.36m | 238.80m | 380.00 | 99.32 | 1.29 | 13.40 | 1.47 | 0.2346 | 0.2346 | 15.76 | 18.03 | 0.5651 | 1.62 | 5.21 | 497,196.30 | 0.8231 | 14.00 | 1.02 | 17.37 | 23.69 | 51.40 | 1.46 | 20.70 | 1.25 | 1.72 | 0.0845 | 0.00 | 18.89 | 21.21 | -17.31 | 4.86 | 15.38 | -- |
Data as of Mar 02 2026. Currency figures normalised to Abionyx Pharma SA's reporting currency: Euro EUR
0.01%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Friedland Gestion SASas of 31 Oct 2025 | 3.50k | 0.01% |
Data from 31 Oct 2025 - 31 Oct 2025Source: FactSet Research Systems Inc.
